A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of oral Tarceva in patients with advanced
NSCLC for whom Tarceva monotherapy is considered the best therapeutic option. The anticipated
time on study treatment is 3-12 months.